ACTIV trials: Lessons learned in trial design in the setting of an emergent pandemic

By sjmartinez • October 31, 2024

Keshtkar-Jahromi M, Anstrom KJ, Barkauskas C, Brown SM, Daar ES, Fischer W, Gibbs KW, Higgs ES, Hughes MD, Jagannathan P, LaVange L, Lindsell CJ, Nayak SU, Paredes R, Parmar M, Peltan ID, Proschan M, Shotwell MS, Vock DM, Yokum T, Adam SJ. ACTIV trials: Lessons learned in trial design in the setting of an emergent pandemic. J Clin Transl Sci. 2024 Oct 15;8(1):e151. doi: 10.1017/cts.2024.1. PMID: 39478775; PMCID: PMC11523015.

Tags: ACTIV, Clinical Trial, covid-19, design, Infectious Diseases, lessons, Publications

Related Posts

Access to HIV treatment during community-wide flooding: Experiences of people living with HIV and health care workers in Malawi, a mixed methods study

Mphande M, Paneno R, Robson I, Phiri K, Cornell M, van Oosterhout JJ, Eisenman DP, Njala J, Phiri S, Dovel K. Access to HIV treatment[...]

Implementation Does Not Occur in a Vacuum: Sustaining a Comprehensive and Global Vision for HIV Research

Gianella S, Lauring A, Paredes R, Croda J, Andes D, Uhlemann AC, Chew K, Stephenson KE, Lewnard JA, John ARO, Leung DT, Clancy CJ, Chu[...]

Recurrent mutations in the stress regulator Cap1 reveal a trade-off between azole resistance and oxidative stress response in Candida albicans

Zhou X, Hilk A, Solis NV, Scott N, Zajac C, Filler SG, Selmecki A. Recurrent mutations in the stress regulator Cap1 reveal a trade-off between[...]